Platelets are the primary target of antithrombotic therapy to prevent cardiovascular events
due to their essential role in atherothrombosis. In patients who have had a recent non …

Cardiologists do not have to obsess about the cause of acute coronary syndromes. In more
than 75% of cases, the cause of the myocardial infarction is plaque rupture with local …

Several studies of patients with stroke, transient ischaemic attack, or atrial fibrillation have
indicated that the combination of two antithrombotic drugs increases the risk of bleeding …

Antiplatelet therapy is recommended for all patients with transient ischaemic attack (TIA) and
ischaemic stroke of arterial origin because it reduces the longterm risk of subsequent stroke …

Meta-analyses have reported that antiplatelet therapy is associated with a 25% reduction in
recurrent ischaemic stroke in patients with a previous stroke or transient ischaemic attack. 1 …

Although 2020 has been marked by the evolution of the COVID-19 pandemic, important
advances in medical research have been reported, particularly in stroke treatment and …

Stroke is the leading cause of disability and the second most common cause of death
worldwide based on the results of the Global Burden of Diseases Study (1). More than 80 …

For any therapeutic intervention, benefits should be balanced against risks. With
antithrombotics for prevention of stroke in patients with a history of stroke or transient …

Anticoagulant therapy to prevent non-cardioembolic ischaemic stroke is not a novel
approach; its use dates back to the 1950s. However, by the 1990s, randomised trials …

After so many trials in the search for a neuroprotective agent failed to improve the outcome
of patients with ischaemic stroke, nihilism began to spread and the door to finding such a …